ABSTRACT

US FDA's commitment to advancing public health through regulatory science and translational medicine is paramount in ensuring the safety, efficacy, and timely availability of medical products. Regulatory science encompasses the application of scientific principles to inform regulatory decision-making, while translational medicine focuses on translating research discoveries into tangible medical interventions. USFDA plays a pivotal role in this field by actively collaborating with stakeholders, researchers, and industry experts to develop and implement rigorous regulatory standards. By fostering innovation and streamlining the approval process, the FDA expedites access to novel therapies without compromising patient safety. Through its dedication to translational medicine, the FDA facilitates the translation of groundbreaking research into practical applications, addressing unmet medical needs and improving patient outcomes. Expedited pathways and breakthrough designations further accelerate the development and review of promising treatments, providing hope for patients facing serious or life-threatening conditions. This study explores the critical role of the FDA in regulatory science and translational medicine and its significant impact on public health advancement by striking a balance between innovation and risk assessment, the FDA remains at the forefront of regulatory agencies worldwide, safeguarding public health while fostering the progress of transformative medical solutions. Keywords: OTS, CDER, Scientific, Data, Research
Publication date: 01/08/2024

https://ijbpas.com/pdf/2024/August/MS_IJBPAS_2024_8261.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.8.8261